Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches

被引：7

作者：

Murugappan, Swaminathan ^{[1
,2
,3
]}

Harris, William P. ^{[1
,2
,3
]}

Willett, Christopher G. ^{[4
]}

Lin, Edward ^{[1
,2
,3
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[2] Seattle Canc Care Alliance, Seattle, WA 98109 USA

[3] Univ Washington, Seattle, WA 98195 USA

[4] Duke Univ, Med Ctr, Div Radiat Oncol, Durham, NC 27710 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 05期

关键词：

TOTAL MESORECTAL EXCISION; PHASE-III TRIAL; PREOPERATIVE RADIOTHERAPY; POSTOPERATIVE CHEMORADIOTHERAPY; ADJUVANT THERAPY; PROGNOSTIC-SIGNIFICANCE; EUROPEAN ORGANIZATION; CLINICAL-SIGNIFICANCE; COLORECTAL-CANCER; RADIATION-THERAPY;

D O I：

10.6004/jnccn.2013.0071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although tumor biology and genomics of colon and rectal cancer are no different, patients with locally advanced rectal cancer (LARC) require neoadjuvant fluoropyrimidine-based chemoradiation and total mesorectal excision. In addition to known clinical risk factors, improved algorithms integrating molecular tools are needed to stratify patients with LARC to improve treatment outcomes and reduce acute and long-term toxicities. Simply combining newer systemic or targeted agents with standard treatment in all patients yielded little success but added toxicities. This article reviews the historical data, current standards of care, and ongoing research efforts regarding biomarkers, molecular imaging, and personalized genomic information.

引用

页码：548 / 557

页数：10

共 86 条

[11] Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer [J].

Craven, I. ;

Crellin, A. ;

Cooper, R. ;

Melcher, A. ;

Byrne, P. ;

Sebag-Montefiore, D. .

BRITISH JOURNAL OF CANCER, 2007, 97 (10) :1333-1337

[12] Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer [J].

Das, Prajnan ;

Skibber, John M. ;

Rodriguez-Bigas, Miguel A. ;

Feig, Barry W. ;

Chang, George J. ;

Wolff, Robert A. ;

Eng, Cathy ;

Krishnan, Sunil ;

Jarl, Nora A. ;

Crane, Christopher H. .

CANCER, 2007, 109 (09) :1750-1755

[13] Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery [J].

den Dulk, M. ;

Marijnen, C. A. M. ;

Collette, L. ;

Putter, H. ;

Pahlman, L. ;

Folkesson, J. ;

Bosset, J. -F. ;

Roedel, C. ;

Bujko, K. ;

van de Velde, C. J. H. .

BRITISH JOURNAL OF SURGERY, 2009, 96 (09) :1066-1075

[14] Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C) [J].

Dewdney, Alice ;

Cunningham, David ;

Tabernero, Josep ;

Capdevila, Jaume ;

Glimelius, Bengt ;

Cervantes, Andres ;

Tait, Diana ;

Brown, Gina ;

Wotherspoon, Andrew ;

de Castro, David Gonzalez ;

Chua, Yu Jo ;

Wong, Rachel ;

Barbachano, Yolanda ;

Oates, Jacqueline ;

Chau, Ian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1620-1627

[15]

DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294

[16]

Duldulao MP, 2012, J CLIN ONCOL S4, V30

[17]

Eisterer WM, 2009, J CLIN ONCOL, V27

[18]

ENKER WE, 1995, J AM COLL SURGEONS, V181, P335

[19]

Fernandez-Martos C, 2011, J CLIN ONCOL, V29

[20] The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer: a practice guideline [J].

Figueredo, Alvaro ;

Zuraw, Lisa ;

Wong, Rebecca K. S. ;

Agboola, Olusegun ;

Rumble, R. Bryan ;

Tandan, Ved .

BMC MEDICINE, 2003, 1 (1)

← 1 2 3 4 5 6 7 8 9 →